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TRPV1 dysfunction in cystinosis 
patients harboring the homozygous 
57 kb deletion
L. Buntinx1, T. Voets2, B. Morlion3, L. Vangeel2, M. Janssen4, E. Cornelissen5, J. Vriens6,  
J. de Hoon1,* & E. Levtchenko6,*
Cystinosis is a rare autosomal recessive disorder characterized by lysosomal cystine accumulation 
due to loss of function of the lysosomal cystine transporter (CTNS). The most common mutation in 
cystinosis patients of Northern Europe consists of a 57-kb deletion. This deletion not only inactivates 
the CTNS gene but also extends into the non-coding region upstream of the start codon of the TRPV1 
gene, encoding the capsaicin- and heat-sensitive ion channel TRPV1. To evaluate the consequences of 
the 57-kb deletion on functional TRPV1 expression, we compared thermal, mechanical and chemical 
sensitivity of cystinosis patients with matched healthy controls. Whereas patients heterozygous for the 
57-kb deletion showed normal sensory responses, homozygous subjects exhibited a 60% reduction in 
vasodilation and pain evoked by capsaicin, as well as an increase in heat detection threshold. Responses 
to cold, mechanical stimuli or cinnamaldehyde, an agonist of the related nociceptor channel TRPA1, 
were unaltered. We conclude that cystinosis patients homozygous for the 57-kb deletion exhibit a 
strong reduction of TRPV1 function, leading to sensory deficiencies akin to the phenotype of TRPV1-
deficient mice. These deficits may account for the reported sensory alterations and thermoregulatory 
deficits in these patients, and provide a paradigm for life-long TRPV1 deficiency in humans.
Cystinosis (OMIM 219800) is rare autosomal recessive disorder (incidence of 1 case per 100,000 to 200,000 live 
births), characterized by lysosomal cystine accumulation causing renal Fanconi syndrome, growth retardation, 
vomiting, periods of dehydration, constipation, and sometimes rickets. Lysosomal cystine accumulation is due 
to an impairment of the lysosomal membrane exodus of cystine, resulting from mutations in the cystinosin gene 
(CTNS) on chromosome 17p13.21,2. More than the half of the alleles of cystinosis patients in Northern Europe are 
affected by a 57-kb deletion3. This deletion not only inactivates the CTNS gene but also removes the entire CARKL 
(carbohydrate kinase like) gene, which encodes a sedoheptulose kinase, and extends into the non-coding region 
of the TRPV1 gene. Freed et al.4 reported reduced TRPV1 mRNA expression in peripheral blood mononuclear 
cells from cystinosis patients homozygous for the 57-kb deletion. Whereas the deletion of the CARKL gene is 
known to result in increased concentrations of sedoheptulose in tissues, plasma and urine of patients5, the poten-
tial (patho)physiological consequences of the 57-kb deletion on TRPV1 gene function are unknown.
TRPV1 (transient receptor potential vanilloid 1), a member of the TRP superfamily of cation chan-
nels, is highly expressed in a subset of primary sensory neurons, more specifically in terminals of small- to 
medium-diameter nociceptors, such as peptidergic and nonpeptidergic C fibers, as well as some Aδ fibers6. 
TRPV1 is directly activated by heat, protons and by a variety of chemical ligands that evoke sensations of heat 
and/or pain, of which the best known example is capsaicin, the pungent compound from hot chili peppers7. In 
the peripheral nervous system, TRPV1 activation is not only associated with pain, but also with neurogenic 
inflammation8. Indeed, activation of TRPV1 at sensory nerve endings causes local release of neuropeptides, 
including calcitonin gene-related peptide (CGRP), which results in vasodilation and edema formation8. Based 
1Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KULeuven, 
Herestraat 49, 3000 Leuven, Belgium. 2Department of Cellular and Molecular Medicine, KULeuven, Herestraat 
49, 3000 Leuven, Belgium. 3Center for algology and pain management, Department of Cardiovascular Sciences, 
KULeuven, Weligerveld 1, 3212 Pellenberg, Belgium. 4Department of internal medicine, Radboud UMC Nijmegen, 
Geert Grooteplein-Zuid 22, 6525 GA Nijmegen, The Netherlands. 5Department of Pediatric Nephrology, Radboud 
UMC Nijmegen, Geert Grooteplein-Zuid 22, 6525 GA Nijmegen, The Netherlands. 6Department of Development and 
Regeneration, KULeuven, Herestraat 49, 3000 Leuven, Belgium. *These authors contributed equally to this work. 
Correspondence and requests for materials should be addressed to L.B. (email: linde.buntinx@uzleuven.be)
received: 01 April 2016
Accepted: 27 September 2016
Published: 13 October 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:35395 | DOI: 10.1038/srep35395
on observations in Trpv1−/− mice, which lack sensitivity to capsaicin and show strongly reduced thermal hyper-
algesia after inflammation and injury, much effort has been devoted to the development of TRPV1 antagonists as 
a potential novel analgesic drugs6,9–11. Several classes of TRPV1 antagonists have been developed, which showed 
efficacy in various preclinical and clinical trials. However, hyperthermia and impaired heat perception were fre-
quent unwanted on-target side effects, raising doubts about the safety of long-term TRPV1 antagonism in clinical 
practice12–15.
Interestingly, several cases of cystinosis patients with disturbances in thermoregulation, such as recurrent 
bouts of fever and heat intolerance, as well as craving for hot and spicy food have been reported, which could 
potentially be related to altered functional expression of TRPV116–18. To evaluate this possibility, we examined 
heat and capsaicin sensitivity in cystinosis patients.
Results
To evaluate the potential influence of the 57-kb deletion on TRPV1 function, we compared chemical, mechanical 
and thermal sensitivity of cystinosis patients that were either homozygous or heterozygous for the deletion, with 
matched healthy controls. Detailed information on mutations in individual patients is provided in Table 1.
Demographics. Comparison of demographics between these three groups is provided in Table 2. No signifi-
cant differences were found in age, blood pressure, heart rate or BMI between the three groups.
All cystinosis patients took cysteamine to treat the cystine accumulation. No difference was found in cysteam-
ine dose (g/m2/day) between patients with homo- or heterozygous 57 kb deletion. Both in the homozygous and 
the heterozygous groups, about half of the patients had a kidney graft and received immunosuppressive treatment. 
There were no significant differences between the two patient groups with respect to the use of anti-hypertensive 
drugs. All patients without kidney graft had renal Fanconi syndrome characterized by polyuria, proteinuria and 
urinary loss of several substances like glucose, amino acids, uric acid, phosphate and bicarbonate. All transplanted 
Pt Sex
Birth 
year Genotype
Renal 
status
Spicy food 
preference
Feeling of disturbed 
thermo- regulationa Comorbiditiesb
1° M 1996 57 kb del + c.926dup FS + − Growth hormone deficiency
2 F 1975 57 kb del + c.926dup Tx − − Growth retardation, kidney stones
3 M 1989 57 kb del + undetected mutationc Tx + − None
4° F 1990 57 kb del + c.198_218del21 Tx − − None
5 F 2003 57 kb del + c.198_218del FS − − None
6 M 1990 57 kb del + c.696dup Tx - + None
7 F 1987 57 kb del + del exon5 Tx − + None
8 M 1987 57 kb del + c.1015G > A Tx + − None
9° F 1995 57 kb del + c.665A > G FS ND ND None
10° F 1995 57 kb del + c.665A > G FS ND ND None
11° M 1986 57 kb del + del exon5 Tx − + None
12*° F 2004 57 kb del + c.926 dup FS − − None
13° F 2005 57 kb del + c.926dup FS − − Genua valga
14° M 1997 57 kb del + c.198_218del21 Tx − − Lumbal scoliosis
15° M 1995 Hom 57 kb del FS ND ND None
16 F 1993 Hom 57 kb del FS ND ND None
17× M 1987 Hom 57 kb del Tx + − Acne vulgaris
18× F 1983 Hom 57 kb del Tx + + Ophthalmologic migraine
19× M 2000 Hom 57 kb del FS + + None
20× F 1997 Hom 57 kb del Tx − + None
21× M 1979 Hom 57 kb del Tx + + Growth retardation
22*° M 1999 Hom 57 kb del FS − + Pes plani and genua valga
23° M 1990 Hom 57 kb del FS + − Buritis elbow
24° F 1992 Hom 57 kb del Tx + + Candida foot nails
25° M 1999 Hom 57 kb del FS − + Genua valga
Table 1.  Patients’ demographics, spicy food preference and thermoregulation. FS: Fanconi Syndrome.  
TX: Renal transplantation. ND: no data. del = deletion, dup = duplication. *These patients (and matching 
healthy volunteers) did not participate in the temperature detection test (Fig. 2a,c). °These patients (and 
matching healthy volunteers) did not participate in the temperature pain threshold test (Fig. 2b,d). ×These 
patients (and matching healthy volunteers) participated in the cinnamaldehyde test (Fig. 1e–g). aSpice food 
preference and thermoregulation based on self-reporting of the patients during exploratory, structured 
interview. bComorbidities at time of measurements. cAlthough the mutation on the second allele in this patient 
couldn’t be detected, the diagnosis of cystinosis was based on elevated white blood cell cystine level and the 
detection of corneal cystine crystals.
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patients had a stable renal function. Body core temperature was normal in all patients. Comorbidities at the 
moment of the study are listed in Table 1.
Reduced capsaicin sensitivity in homozygous patients. To investigate capsaicin sensitivity, a 
capsaicin-containing solution or vehicle was applied in small rubber rings on the volar surface of the left arm, and 
Laser Doppler scanning was performed at 10-min interval to measure capsaicin-induced changes in dermal blood 
flow (DBF). In addition, the Numerical Rating Scale (NRS)-11 pain scale was used to quantify capsaicin-induced 
pain at these time points. In healthy volunteers, capsaicin induced a large increase in DBF during the first 40 min-
utes of application, as well as a clear pain response that peaked at 20 minutes. In contrast, capsaicin responses were 
blunted in cystinosis patients homozygous for the 57-kb deletion: the onset of the DBF response was delayed, 
and both the objective peak DBF response as well as the subjective pain levels were reduced by more than 60% 
compared to healthy volunteers. Notably, in heterozygous patients capsaicin-induced changes in DBF and pain 
responses were not significantly different from the healthy controls (Fig. 1a–d). The same results were found when 
excluding patients who received a kidney graft, which suggests that DBF responses were not noticeably influenced 
by immune suppressive treatment used after renal transplantation (Suppl. Fig. 1). These results indicate that 
reduced capsaicin sensitivity is not a general property of cystinosis patients but only of patients with bi-allelic 
deletion of the 57-kb genomic fragment.
Capsaicin-induced increases in DBF are the result of the release of vasoactive peptides such as CGRP from 
nerve terminals in the skin8. To exclude the possibility that the reduced DBF response in the homozygous patients 
was secondary to impaired neuropeptide release from terminals and/or reduced responsiveness of the vascu-
lature to these neuropeptides, we developed an assay in which we evaluated changes in DBF evoked by topical 
cinnamaldehyde. Cinnamaldehyde is an agonist of TRPA1, a nociceptor ion channel that is highly co-expressed 
with TRPV1 in nerve terminals, and whose activation causes CGRP release in animal models19–22. We found that 
cinnamaldehyde evokes robust increases in DBF, and these increases were virtually identical in the homozygous 
patients and the healthy volunteers (Fig. 1e–g). In addition, all three groups showed a similar response to the 
placebo (= vehicle) solutions used for both capsaicin and cinnamaldehyde (Fig. 1b,c,f,g).
Deficit in heat sensitivity in homozygous patients. Since TRPV1 is a heat-activated channel, and has 
been implicated in heat sensing and thermoregulation in animal models and humans, we compared sensitivity to 
heating and cooling in the homo- and heterozygous patients to that in healthy volunteers. Analogous to earlier 
work in patients with persistent pain and healthy controls23, we evaluated both the temperatures at which the sub-
jects first detected a change in temperature (heat/cold detection threshold), as well as the temperatures at which 
the warming or cooling evoked pain (heat/cold pain thresholds). Homozygous patients showed a significantly 
higher heat detection threshold (35.7 ± 0.6 degrees) compared to healthy volunteers (34.3 ± 0.6 degrees; Fig. 2a). 
Heat pain thresholds were not significantly different between the groups, although it should be noted that, in line 
with the literature23, this parameter showed fairly large interindividual variability, thereby reducing the power of 
the comparison. We also did not detect any significant differences between the three groups with respect to their 
cold detection or cold pain thresholds (Fig. 2c,d). To evaluate whether the 57-kb deletion in cystinosis has a more 
general effect on somatosensory sensitivity, we also assayed skin mechanosensitivity using von Frey hairs. These 
experiments revealed no noticeable differences in detection threshold or pain threshold between the three groups, 
indicating that mechanosensitivity is not affected in cystinosis (Fig. 2e).
Parametera
Healthy volunteers 
(n = 25)
Heterozygous 
patients (n = 14)
Homozygous 
patients (n = 11)
Age - yrs. 20.7 ± 1.2 20.3 ± 2.0 21.2 ± 2.0
Male sex – no (%) 13 (52) 6 (42) 7 (63)
BMI - kg/m2 20.7 ± 1.4 20.5 ± 1.0 19.4 ± 1.0
Kidney graft – no (%) NA 57% 54%
BP 
 Systolic BP - mmHg 120 ± 2 121 ± 3 120 ± 4
 Diastolic BP- mmHg 67 ± 2 72 ± 3 72 ± 3
 HR –bpm 69 ± 2 74 ± 3 77± 4
 Smoker–no (%) 0 (0) 1 (7) 1 (9)
Medication use – no (%)
 Anti-hypertensives NA 9 (78) 9 (81)
 Immunosuppressive drugs NA 6 (57) 6 (54)
 Cysteamine (mg/m2/day) NA 1.19 ± 0.13 1.34 ± 0.11
 Body temperature (°C)b NA 36.4 ± 0.2 36.5 ± 0.4
Table 2.  Summary demographics of all 3 groups. aPlus-minus values are means ± SEM. There were no 
significant differences between the groups (p > 0.05). bBody temperature measurements were based on 
temperature measurements recorded in the medical files of the patients during the year of the study. NA = not 
applicable.
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Correlation with subjective reporting. There are several, mostly anecdotal reports in the literature that 
cystinosis patients have a more frequent preference for spicy food or disturbances in thermoregulation than 
healthy subjects, but whether this is related to TRPV1 dysfunction is unknown. To address whether the objec-
tively determined alterations in capsaicin sensitivity and thermosensation in the homozygous patients correlated 
with their subjective experiences in daily life, we performed a short structured interview in both hetero- and 
homozygous patients who were asked (1) whether they had a preference for spicy food, and (2) whether they 
had the feeling that the regulation of their body temperature was disturbed. Interestingly, 67% (6 out of 9) of the 
homozygous patients reported a strong preference for spicy food, compared to only 25% of the heterozygous 
patients (3 out of 12; p = 0.039). Likewise, 78% (7 out of 9) of the homozygous patients reported subjective ther-
mosensory/thermoregulatory problems, such as hot flashes, difficulties in adapting to changes in temperature or 
difficulties in sensing temperature differences, compared to only 25% of the heterozygous patients (3 out of 12; 
p = 0.014).
Figure 1. Sensitivity of cystinosis patients to topical application of capsaicin or cinnamaldehyde. (a) LDI 
images showing responses to topical capsaicin application in a healthy volunteer and in a heterozygous and 
a homozygous cystinosis patient. (b) Mean time course of the DBF expressed as % change from baseline in 
response to capsaicin or placebo (= vehicle), in healthy volunteers (n = 25), heterozygous patients (n = 14) 
and homozygous patients (n = 11). (c) Mean area under the curve for the data in (b). (d) Capsaicin induced 
pain, expressed in NRS-11 over time for the subjects in (b). (e) LDI images showing responses to topical 
cinnamaldehyde application in a healthy volunteer and in a homozygous cystinosis patient. (f) Mean 
time course of the DBF expressed as % change from baseline in response to cinnamaldehyde or vehicle, in 
healthy volunteers (n = 5) and homozygous patients (n = 5). (g) Mean area under the curve for the data 
in (f). *p < 0.05 between homozygous patients and healthy volunteers. °p < 0.05 between homozygous 
patients and heterozygous patients (Kruskall-Wallis with post-hoc Dunn’s (capsaicin) or Mann-Whitney-U 
(cinnamaldehyde)) N.S.: Non-significance. Data are presented as mean ± SEM.
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Discussion
In this study, we provide evidence that homozygous deletion of the 57-kb fragment in cystinosis patients results in 
functional impairment of the TRPV1 receptor, as evidenced by a strongly reduced responsiveness to the selective 
TRPV1 activator capsaicin. The reduced capsaicin-induced vasodilation and pain responses in the homozygous 
patients recapitulate the reduced pain response and vasodilation reported both in TRPV1-deficient mice and in 
humans treated with TRPV1 antagonists9,24,25. Importantly, the reduced response to capsaicin was not the con-
sequence of an overall deficit in vasodilation or sensitivity to chemical irritants, as homozygous patients showed 
unaltered vasodilatory responses to cinnamaldehyde, an agonist of the related nociceptor channel TRPA1.
In addition to the strong deficiency in capsaicin sensitivity, we also measured milder alterations in heat sensi-
tivity in the homozygous patients. In particular, these patients had a significantly higher threshold for detecting 
a heating stimulus. Their average threshold for heat pain was 46.7 ± 2.0 degrees compared to the threshold of 
healthy volunteers 44.7 ± 1.5 degrees, but no significant difference was found (p = 0.6), possibly due to the limited 
size of the patients group that we have access to, combined with the established inter-individual differences in heat 
pain thresholds26. It should be noted here that even in mice the effects of TRPV1 deletion on acute noxious heat 
sensing are, at best, very mild. Indeed, in the initial descriptions of Trpv1−/− mice, Caterina et al. reported longer 
withdrawal latencies in the hot plate test, but only at temperatures exceeding 52 degrees, whereas Davis et al. 
 reported unaltered nocifencive behavior in the hot plate assay9,27. Similarly, in human volunteers treated with 
the TRPV1 antagonist SB-705498, noxious heat thresholds were increased by not more than 1–2 degrees24. There 
is accumulating evidence for the existence of additional noxious heat sensors in the sensory system, including 
Figure 2. Sensitivity of cystinosis patients to thermal and mechanical stimuli. (a–d): Heat detection 
thresholds (a), heat pain thresholds (b), cold detection thresholds (c) and cold pain thresholds (d) in healthy 
volunteers, heterozygous patients and homozygous patients. (e) Detection thresholds and pain thresholds for 
mechanical stimuli applied via von Frey hairs in healthy volunteers, heterozygous patients and homozygous 
patients. *p < 0.05 between homozygous patients and healthy volunteers (Kruskall-Wallis with post-hoc Dunn’s 
or One-way ANOVA with post-hoc Bonferroni). N.S.: Non-significance. Data are presented as mean ± SEM.
www.nature.com/scientificreports/
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other TRP channels (TRPM3, TRPV3, TRPV4) and the heat-sensitive calcium-activated chloride channel ANO1 
(TMEM16A), which may (at least partially) compensate for the loss of TRPV1 function in detecting acute heat 
stimuli in mice and humans26,28–30.
Since heterozygous cystinosis patients, who all lacked functional cystinosin due to the 57-kb deletion on one 
allele and another CTNS mutation on the other allele, did not exhibit any difference in capsaicin responses or heat 
sensitivity compared to healthy subjects, we can exclude that reduced capsaicin sensitivity represents a general 
effect of the disease cystinosis (or of the drugs taken to manage the disease and/or kidney transplant) on sen-
sory processes or vascular responses. Instead, it suggests that the sensory deficit represents a direct consequence 
of homozygous 57-kb deletion on functional TRPV1 expression. The phenotype observed in our heterozygous 
patients is also in line with Trpv1+/− mice, which show no difference in their responses to capsaicin and temper-
ature compared to the wild-type mice27.
The depletion of the sedoheptulose kinase CARKL is reportedly associated with increased immune response27, 
however, we consider it unlikely that the reduced vascular response to capsaicin is related to the deletion of the 
CARKL gene in the homozygous patients. The TRPV1 dependence of the sensory deficit is further supported by 
our finding that neither vasodilatation in response to the TRPA1 agonist cinnamaldehyde, nor responses to cold 
or mechanical stimuli were affected in the homozygous patients.
In spite of the reduced TRPV1 functionality, the homozygous patients generally presented with a normal core 
body temperature. This may seem at odds with studies showing that healthy volunteers dosed with first generation 
TRPV1 antagonists exhibited mild to severe hyperthermia13,14,31,32. However, it was also shown that these hyper-
thermic response disappeared upon repeated dosing12. Moreover, recent evidence suggests that modality-specific 
antagonists, which inhibit TRPV1 activity induced by heat or capsaicin but not by protons, do not markedly affect 
body temperature33. Finally, the Trpv1−/− mice also showed a normal core body temperature. Taken together, 
our and others’ data indicate that pharmacological or genetic reduction of TRPV1 activity in humans does not 
necessarily result in permanent alternations of body core temperature. Moreover, considering the role of TRPV1 
in pathological pain conditions, the non-coding region upstream of the TRPV1 gene could be a possible target 
to reduce functional TRPV1 for therapeutic reasons. However, further evidence is required to validate whether 
homozygous patients have altered inflammatory pain experiences.
There have been anecdotal reports of cystinosis patients preferring hot and spicy food, or exhibiting dis-
turbances in thermoregulation16–18, but whether this correlated with altered TRPV1 functionality remained 
unknown. To address this issue, we asked both heterozygous and homozygous cystinosis patients whether 
they preferred spicy food or felt that they experienced problems with thermosensation or thermoregulation. 
Interestingly, 67% of the homozygous patients reported a preference for spicy food and 78% reported subjective 
thermosensory or thermoregulatory deficits, such as difficulties in sensing small temperature differences or the 
occurrence of hot flashes. In comparison, only 25% of the heterozygote patients made similar reports. We spec-
ulate that these self-reported daily life experiences in the homozygous patients are a direct consequence of the 
reduced TRPV1 functionality in their sensory neurons, which impairs their ability to respond to challenges of 
their thermoregulatory system, and renders them less sensitive to capsaicin-rich spicy food. Considering that 
objective parameters such as blood pressure and body core temperature in the homozygous patients were normal 
and indistinguishable from that in the heterozygous patients, we estimate that the physiological consequences 
of the reduced TRPV1 functionality are overall mild. More systematic studies are required to confirm these 
observations.
Our study did not unravel the exact genomic mechanism whereby the 57-kb deletion affects functional 
expression of TRPV1. A possible explanation is that the 57-kb deletion influences the interaction of transcription 
factors that regulate TRPV1 expression4. In line herewith, it has been reported that TRPV1 mRNA levels are 
reduced in peripheral blood mononuclear cells from homozygous patients4. It should be noted, however, that 
functional expression of TRPV1 in non-sensory cells such as blood cells is low, and that transcriptional regulation 
of TRPV1 expression is likely to be different in sensory neurons28,34,35. Unfortunately, since it is not possible to 
sample sensory neurons from living patients, we had no means to measure TRPV1 expression at the mRNA level 
in these cells. Nevertheless, our current findings provide the first direct evidence that the genomic deletion results 
in actual functional deficits in the sensory system that can be directly linked to the known properties of TRPV1.
In conclusion, we demonstrate that cystinosis patients homozygous for the 57-kb deletion exhibit a significant 
reduction in capsaicin-induced dermal vasodilatation and pain, and thus provide a paradigm for life-long TRPV1 
dysfunction in humans.
Methods
Patients and healthy volunteers. Cystinosis patients were recruited from the University Hospitals 
Leuven, Belgium and the University Medical Center Radboud Nijmegen, the Netherlands. The diagnosis of cys-
tinosis was based on the clinical presentation, measurement of elevated white blood cell cystine levels and con-
firmed by a molecular analysis of the CTNS gene. Healthy volunteers were recruited via the Center for Clinical 
Pharmacology, University Hospitals Leuven. The study was approved by the Ethics Committees of both hospitals 
(BE: registration nr.: ML8725, approved at 16 Nov 2012; NL: registration nr.: 2013/122/NL42764.091.12, approved 
at 14 May 2013) and conducted according to the declaration of Helsinki and International Guidelines on Clinical 
Trials of Medicinal Products (ICH/GCP Topic E6–July 1996) (ClinicalTrials.gov identifier: NCT02533076). All 
participants (or their parents when < 18y) provided written informed consent prior to their participation in the 
study.
Male and female participants were eligible if they were > 8 years and did not have any abnormalities of the 
forearm skin or allergies to capsicum plants. All participants refrained from alcohol or caffeine for at least 12 
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hours and fasted for 3 hours before the study visit. Healthy volunteers had to be good health and took no medica-
tion. Patients and healthy volunteers were matched head-to-head based on age and sex.
Mutational analysis of the CTNS gene. 57 kb deletion was detected by PCR analysis as described by 
Heil et al.3. Direct Sanger sequencing of the CTNS coding exons and exon-intron boundaries was performed to 
detect other mutations.
Laser Doppler imaging & capsaicin application. Three O-shaped rubber rings (Quad Ring BS011 NBR 
70 Shore A; Polymax Ltd) were placed on the volar site of the left arm of the subject. After 30 minutes of acclima-
tization, baseline DBF was measured and 10 minutes hereafter, capsaicin was applied in the two proximal rings 
(referred to as I1 and I2) and placebo in the distal ring (I3).
Capsaicin powder and Trans-cinnamaldehyde oil were obtained from Sigma-Aldrich N.V. (Bornem, Belgium). 
Capsaicin was dissolved in a 3:3:4 mixture of ethanol 100%, Tween-20 and distilled water to obtain a 300 μ g/20 μ 
l (for subjects < 18 years old) or 1000 μ g/20 μ l (>18 years old) concentration. The 1000 μ g/20 μ l dose of capsaicin 
was used in adults as previous studies reported that this dose produces the most robust response36. In children 
(< 18y old), 300 μ g/20 μ l was used based on pilot experiments showing that 300 μ g capsaicin already induced a 
strong pain response, and that the DBF response was as robust as the 1000 μ g dose in adults (data not shown). 
Trans-cinnamaldehyde oil was dissolved in a 3:3:1 mixture of ethanol 100%, Tween-20 and distilled water to 
obtain a 10% concentration. The placebo solution corresponded to the same mixtures without the active sub-
stances. The 300- or 1000-μ g dose capsaicin or the 10% cinnamaldehyde were always applied in the two proxi-
mal rings, placebo in the distal ring. The application of capsaicin/trans-cinnamaldehyde started on I1. The laser 
Doppler scans were performed 10 minutes after application of capsaicin/transcinnamaldehyde, using the Laser 
Doppler perfusion imager (Periscan PIM III, Perimed AB, Sweden). During 40 minutes, the 3 rings on the left arm 
were scanned every 10 minutes. This capsaicin DBF model has been used extensively in clinical studies, developed 
and validated by Van der Schueren et al.36. Sample size calculations were also based on Van der Schueren et al.36.
Numerical rating scale (NRS-11). The pain level induced by the capsaicin was determined by asking the 
subject to score his pain with the numerical rating scale (NRS-11). Zero stood for ‘no pain at all’ and 10 ‘the worst 
pain you could imagine’. The pain level was determined at baseline (i.e. after 30 minutes of acclimatization) and 
10, 20, 30 and 40 minutes after capsaicin application.
Von Frey test. A set of 17 monofilaments (Somedic, Sweden), marked 3 to 19 with different diameters 
(0.12–1 mm), was applied in ascending and descending sequence on the skin of the forearm on the area of capsa-
icin application with appropriate force (0.026–110 g) for it to obtain a U-shape. Each filament was applied 3 times 
to the skin with intervals of 1 second. The subjects were asked to report how many times they felt the application 
and how many times the application was painful.
Advanced thermal stimulation. The sensitivity of the skin for temperature, hot and cold, was determined 
using the advanced thermal stimulator (ATS) (Pathway ATS, Medoc, Israel). The device uses a thermode (contact 
area of 27 mm diameter), with a baseline temperature of 32 °C, that was attached to the thenar eminence at the base 
of the thumb. The method used was the method of limits as described by Rolke et al.37,38 and Malmström et al.23. 
First, the detection threshold for cold was determined by cooling down the thermode 4 times (10 seconds 
inter-stimuli intervals) at a rate of 1 °C/second, starting from the baseline temperature of 32 °C. The subject 
was asked to click immediately on a computer mouse when the decrease in temperature was noticed. This was 
done in a similar way to find the detection threshold for heat, now by for warming up the thermode at a rate of 
1 °C/second. Next, cold and heat pain thresholds were determined. Here, the subject was asked to click on the 
computer mouse when the temperature of the thermode became ‘painful’. This was repeated 3 times (10 seconds 
inter-stimuli intervals) for both heating and cooling down of the thermode with a rate of 1 °C/second, starting 
from the baseline temperature of 32 °C.
Patients’ interview. A short, exploratory structured interview was performed by the investigator, during 
which the following two questions were asked (translated from Dutch): (1) “Do you have a preference for spicy 
food?”, and (2) “Do you have the feeling that the regulation of your body temperature is disturbed?”
Statistical analyses. Values are expressed as means ± standard error of the mean.
When comparing between 3 independent groups, one-way ANOVA was performed for continuous nor-
mally distributed variables (temperature induced pain, demographics) and Kruskall-Wallis test was performed 
for continuous non-normally distributed (CIDBF, AUC, temperature perception) or discrete variables (NRS-11, 
Von Frey scores). Shapiro-Wilk test was used to check for normality. Levene’s test was used to check equality 
of variances. Post-hoc Bonferroni or Dunn’s multiple comparison test was used to correct for multiple testing. 
When comparing two independent groups with small sample size (cinnamaldehyde induced DBF and AUC), the 
Mann-Whitney test was used. For analysis of the data from the exploratory, structured interview, Barnard’s exact 
test was used. Statistical significance was taken at the 5% level (p value < 0.05). Statistical software of Statistica® 
and Graphpath Prism® was used.
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